SAN DIEGO, July 19, 2012 /PRNewswire-iReach/ -- FirstMark, provider of the groundbreaking cardiovascular blood test PREvent, announced the meeting of the Scientific Advisory Board, held today on July 19, 2012. The July meeting focused on the selection and planning of future clinical validation studies, designed according to the following priorities: an independent clinical validation of the test for coronary artery disease patients, expansion of clinical utilization of the test to a more generalized population, validation of improved outcomes with PREvent testing for medical management optimization, and the impact of the test on health economics.
"Each member of our prestigious Scientific Advisory Board has made extraordinary contributions to cardiovascular medicine and research. We are honored to have their expertise as we move into this next phase for PREvent. It's an exciting time for FirstMark, now that PREvent has gained momentum for clinical adoption, especially among primary care physicians and internists" says Thomas Silberg, President and CEO of GenWay Biotech. "PREvent's launch was based on the remarkable data resulting from the 4-year, 3,414 cohort study at Emory University. We look forward to implementing plans based on the advice of our scientific advisors for the selected future trials that will uncover additional benefits of PREvent for coronary artery disease patients, and expand utility of the test to other patient populations. Most importantly, the future clinical validation studies are designed to provide evidence that PREvent can improve outcomes for patients tested with PREvent, and have an impact on overall health economics of coronary artery disease patients' management."
The FirstMark Scientific Advisory Board is comprised of prominent cardiologist and research scientists including:
George A. Beller, MD, MACC
Cardiologist, University of Virginia Health System
Past President of the America
Copyright©2012 PR Newswire.
All rights reserved